NextPharma Technologies, also known as NextPharma San Diego (and sometimes known as Bioserv) provides contract manufacturing services to biotechnology, pharmaceutical, diagnostic, and medical device companies. Its facilities can prepare the small batches of biological drugs and placebos used in clinical trials. It can produce solid, liquid, and semi-solid products, as well as injectable drugs. It also offers clinical trial support services and pharmaceutical logistics services. The company's customers include both small and large multinational health care corporations. NextPharma Technologies is the US subsidiary of the UK's NextPharma Technologies Holding Ltd.

Monogram Biosciences, Inc. Diagnostics company operates in the growing field of personalized medicine, creating laboratory tests that help doctors tailor treatments for infectious disease and cancer patients based on the patients' genetic traits. Its PhenoSense and GenSeq tests determine patients' drug resistance to various classes of HIV drugs. It has also introduced its Trofile assay, which helps doctors choose patients who will be responsive to a new class of HIV drugs called CCR5 antagonists. Monogram markets its products to doctors and reference laboratories (for patient treatment) and to drug researchers (for clinical trials). The company was acquired by LabCorp in 2009.

Ligand Pharmaceuticals Incorporated company was founded in 1987. Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that focuses on drug discovery and early-stage development of pharmaceuticals that address critical unmet medical needs or that are more effective and/or safer than existing therapies, more convenient to administer and are cost effective. The Company has research and development collaborations for its product candidates with numerous pharmaceutical companies. These collaborations include ongoing clinical programs at Bristol-Myers Squibb (BMS), GlaxoSmithKline (GSK), Pfizer, Schering-Plough, Wyeth, Cephalon and Celgene. It receives royalty revenues from King Pharmaceuticals (King), and GSK. In February 2007, it completed the sale of its AVINZA product line to King. Through October 2008, it received a 15% royalty on AVINZA net sales. On December 23, 2008, it acquired all of the outstanding common shares of Pharmacopeia, Inc. In December 2009, Ligand Pharmaceuticals Incorporated acquired Neurogen Corporation.

Medivation, Inc. was founded in 2003 and is based in San Francisco, California. Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and castration-resistant prostate cancer. Its product pipeline includes Dimebon, which is in pivotal Phase 3 trial in patients with mild-to-moderate Alzheimer's disease, and is in Phase 2 clinical trial in patients with mild-to-moderate Huntington's disease; and MDV3100, a Phase 1-2 clinical trial product in patients with castration-resistant prostate cancer. The company has a collaboration agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases, as well as an agreement to develop and commercialize MDV3100, an investigational drug for the treatment of prostate cancer.

Hana Biosciences, Inc. company was founded in 2002 and is based in South San Francisco, California. Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The company's supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer.

Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts. Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology.

Adherex Technologies researches and develops cancer treatments. One of its lead drug candidates targets a tumor's blood supply and makes those blood vessels weak and leaky by disrupting a key protein. Other potential therapies could make cancer cells more vulnerable to anti-cancer drugs or help prevent hearing loss in children undergoing certain types of chemotherapy. Adherex Technologies' pipeline is strongly based on compounds that disrupt cadherins, proteins that adhere like molecules together in cell adhesion. Southpoint Capital Advisors own a controlling stake in the company.

Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).

Kent International Holdings, Inc. was founded in 1982 and is based in Far Hills, New Jersey. Kent International Holdings, Inc. (Kent International), formerly Cortech, Inc. was a biopharmaceutical company whose primary focus had been the discovery and development of therapeutics for the treatment of inflammatory disorders. It had directed its research and development efforts principally toward protease inhibitors and bradykinin antagonists. The Company has not identified the particular business, which it will seek to engage, nor has it conducted any market studies with respect to any business or industry to evaluate the possible merits or risks of the target business or industry, which the Company ultimately may operate.

Tekmira Pharmaceuticals is giving diseases the silent treatment. The biopharmaceutical company is attempting to develop therapies that inhibit or "silence" certain disease-causing genes through ribonucleic acid interference (RNAi), a mechanism that disrupts the production of proteins that can lead to cancer, metabolic, and infectious diseases. Tekmira's lead candidates are being developed to treat tumors and high cholesterol. It also partners with other pharmaceutical companies, such as Alnylam Pharmaceuticals and Roche, to advance additional RNAi products using Tekmira's stable nucleic acid-lipid particles (SNALP) RNAi drug delivery technology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.